These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28391970)

  • 1. Novel 5-HT
    Canale V; Partyka A; Kurczab R; Krawczyk M; Kos T; Satała G; Kubica B; Jastrzębska-Więsek M; Wesołowska A; Bojarski AJ; Popik P; Zajdel P
    Bioorg Med Chem; 2017 May; 25(10):2789-2799. PubMed ID: 28391970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
    Canale V; Kurczab R; Partyka A; Satała G; Lenda T; Jastrzębska-Więsek M; Wesołowska A; Bojarski AJ; Zajdel P
    Eur J Med Chem; 2016 Jan; 108():334-346. PubMed ID: 26698537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-Alkylated arylsulfonamides of (aryloxy)ethyl piperidines: 5-HT(7) receptor selectivity versus multireceptor profile.
    Canale V; Kurczab R; Partyka A; Satała G; Słoczyńska K; Kos T; Jastrzębska-Więsek M; Siwek A; Pękala E; Bojarski AJ; Wesołowska A; Popik P; Zajdel P
    Bioorg Med Chem; 2016 Jan; 24(2):130-9. PubMed ID: 26706111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.
    Brennan JA; Graf R; Grauer SM; Navarra RL; Pulicicchio CM; Hughes ZA; Lin Q; Wantuch C; Rosenzweig-Lipson S; Pruthi F; Lai M; Smith D; Goutier W; van de Neut M; Robichaud AJ; Rotella D; Feenstra RW; Kruse C; Broqua P; Beyer CE; McCreary AC; Pausch MH; Marquis KL
    J Pharmacol Exp Ther; 2010 Jan; 332(1):190-201. PubMed ID: 19828876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel N-acyl-carbazole derivatives as 5-HT7R antagonists.
    Kim Y; Yeom M; Tae J; Rhim H; Choo H
    Eur J Med Chem; 2016 Mar; 110():302-10. PubMed ID: 26852005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antidepressant-like activity of novel aralkyl piperazine derivatives targeting SSRI/5-HT
    Gu ZS; Zhou AN; Xiao Y; Zhang QW; Li JQ
    Eur J Med Chem; 2018 Jan; 144():701-715. PubMed ID: 29291438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropharmacological and antidepressant-like effects of ZY-1408: A novel serotonin/norepinephrine reuptake inhibitor and serotonin receptor 2C antagonist.
    Gao N; Tiliwaerde M; Zheng W; Xiong J; Li X; Jin Z
    Neuropharmacology; 2021 Jan; 182():108376. PubMed ID: 33122031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of the halogen bonding on D
    Partyka A; Kurczab R; Canale V; Satała G; Marciniec K; Pasierb A; Jastrzębska-Więsek M; Pawłowski M; Wesołowska A; Bojarski AJ; Zajdel P
    Bioorg Med Chem; 2017 Jul; 25(14):3638-3648. PubMed ID: 28529043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.
    Sarkisyan G; Roberts AJ; Hedlund PB
    Behav Brain Res; 2010 May; 209(1):99-108. PubMed ID: 20097233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
    Kołaczkowski M; Marcinkowska M; Bucki A; Pawłowski M; Mitka K; Jaśkowska J; Kowalski P; Kazek G; Siwek A; Wasik A; Wesołowska A; Mierzejewski P; Bienkowski P
    J Med Chem; 2014 Jun; 57(11):4543-57. PubMed ID: 24805037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
    Orjales A; Mosquera R; Toledo A; Pumar MC; García N; Cortizo L; Labeaga L; Innerárity A
    J Med Chem; 2003 Dec; 46(25):5512-32. PubMed ID: 14640559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and sustained antidepressant properties of an NMDA antagonist/monoamine reuptake inhibitor identified via transporter-based virtual screening.
    Talbot JN; Geffert LM; Jorvig JE; Goldstein RI; Nielsen CL; Wolters NE; Amos ME; Munro CA; Dallman E; Mereu M; Tanda G; Katz JL; Indarte M; Madura JD; Choi H; Leak RK; Surratt CK
    Pharmacol Biochem Behav; 2016; 150-151():22-30. PubMed ID: 27569602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
    Caldarone BJ; Paterson NE; Zhou J; Brunner D; Kozikowski AP; Westphal KG; Korte-Bouws GA; Prins J; Korte SM; Olivier B; Ghavami A
    J Pharmacol Exp Ther; 2010 Dec; 335(3):762-70. PubMed ID: 20864506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT
    Kucwaj-Brysz K; Kurczab R; Jastrzębska-Więsek M; Żesławska E; Satała G; Nitek W; Partyka A; Siwek A; Jankowska A; Wesołowska A; Kieć-Kononowicz K; Handzlik J
    Eur J Med Chem; 2018 Mar; 147():102-114. PubMed ID: 29425815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and Synthesis of Arylamidine Derivatives as Serotonin/Norepinephrine Dual Reuptake Inhibitors.
    Wen H; Qin W; Yang G; Guo Y
    Molecules; 2019 Jan; 24(3):. PubMed ID: 30704101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and antidepressant activity of a series of arylalkanol and aralkyl piperazine derivatives targeting SSRI/5-HT
    Gu ZS; Xiao Y; Zhang QW; Li JQ
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5420-5423. PubMed ID: 29138029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests.
    Takahashi E; Katayama M; Niimi K; Itakura C
    Eur J Pharmacol; 2008 Jul; 589(1-3):149-56. PubMed ID: 18571641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel N-biphenyl-2-ylmethyl 2-methoxyphenylpiperazinylalkanamides as 5-HT7R antagonists for the treatment of depression.
    Kim Y; Tae J; Lee K; Rhim H; Choo IH; Cho H; Park WK; Keum G; Choo H
    Bioorg Med Chem; 2014 Sep; 22(17):4587-96. PubMed ID: 25127461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
    Martínez-Esparza J; Oficialdegui AM; Pérez-Silanes S; Heras B; Orús L; Palop JA; Lasheras B; Roca J; Mourelle M; Bosch A; Del Castillo JC; Tordera R; Del Río J; Monge A
    J Med Chem; 2001 Feb; 44(3):418-28. PubMed ID: 11462981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS).
    Liang Y; Shaw AM; Boules M; Briody S; Robinson J; Oliveros A; Blazar E; Williams K; Zhang Y; Carlier PR; Richelson E
    J Pharmacol Exp Ther; 2008 Nov; 327(2):573-83. PubMed ID: 18689611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.